Exploring novel biomarkers in multiple myeloma

Description

Abstract
This presentation investigates the diagnostic and therapeutic potential of plasma Galectin-3 and circulating microRNAs (miRNAs) in Multiple Myeloma (MM) progression. MM evolves from precursor stages such as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smouldering Multiple Myeloma (SMM), with progression influenced by genetic alterations and interactions within the bone marrow microenvironment.
Galectin-3, a β-galactoside-binding lectin, plays a key role in bone remodelling and immune suppression through its interaction with Lymphocyte Activation Gene-3 (LAG-3) and modulation of osteoclast activity. Elevated plasma Galectin-3 levels in symptomatic MM, especially in patients with lytic bone lesions, suggest its involvement in bone pathology and disease advancement.
The study also identifies several differentially expressed miRNAs, including miR-133a-3p and miR-146a-5p, which are significantly upregulated in symptomatic MM. Notably, miR-133a-3p correlates with Galectin-3 levels, indicating a functional miRNA–Galectin-3 axis that may contribute to osteoclast-mediated bone resorption. These findings provide a framework for future studies aimed at elucidating the miRNA–Galectin-3 axis in MM pathogenesis and highlight the potential of these biomarkers as predictive tools and therapeutic targets in Multiple Myeloma.

Period	24 Sept 2025
Event title	IBMS congress 2025
Event type	Conference
Location	BriminghamShow on map
Degree of Recognition	National